# Evaluation of Safety and Efficacy of Specific Immunotherapy With Recombinant Major Allergens of Timothy Grass Pollen Adsorbed Onto Aluminium-hydroxide in Patients With IgE-mediated Allergic Rhinoconjunctivitis +/- Controlled Asthma

> **NCT00671268** · PHASE3 · COMPLETED · sponsor: **Allergopharma GmbH & Co. KG** · enrollment: 256 (actual)

## Conditions studied

- Rhinoconjunctivitis

## Interventions

- **BIOLOGICAL:** AL0704rP
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT00671268
- **Lead sponsor:** Allergopharma GmbH & Co. KG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2012-03
- **Final completion:** 2013-03
- **Target enrollment:** 256 (ACTUAL)
- **Last updated:** 2013-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00671268

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00671268, "Evaluation of Safety and Efficacy of Specific Immunotherapy With Recombinant Major Allergens of Timothy Grass Pollen Adsorbed Onto Aluminium-hydroxide in Patients With IgE-mediated Allergic Rhinoconjunctivitis +/- Controlled Asthma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00671268. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*